Marco Meglio

At 6 months, 62% of the 10 kHz spinal cord stimulation treatment group had observed improvement upon investigator-assessed neurological examination, compared to 3% of conventional medical management subjects.

Patients with highly refractory status epilepticus had greater median hospital length stays as well as greater median hospital costs compared to patients with moderate or low refractory status epilepticus.

Treatment with fingolimod followed by alemtuzumab led to an increase in spinal relapses as well as increased risk of secondary autoimmunity.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the issues that remain with enrolling patients into real-world dementia trials and standardizing measures.

Antisense-mediated reduction of mutant FUS protein previously showed prevention of motor neuron loss in an FUS-ALS mouse model.

Annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status were all superior in the ponesimod-treated group.

A majority of patients across all 3 cohorts maintained or improved their motor function shown by changes from baseline in Revised Hammersmith Scale scores.

Overall, 91% of participants in the pooled bimagrumab group and 89.1% in the placebo group had at least 1 or more treatment-emergent adverse event.

The consultant in the department of neurology at Mayo Clinic detailed a number of topics surrounding Parkinson Disease Awareness Month, including the progress made in the last 2 decades.

Patients with a history of abuse reported a higher average or median questionnaire scores that focused on anxiety, depression, photophobia, hyperacusis, ictal allodynia, and interictal allodynia.

Alzheimer disease-related neurodegeneration was correlated only with the thickness of the ganglion cell-inner plexiform layer.

There were no significant treatment group differences for measures of Alzheimer disease regional atrophy, cerebral blood flow, or mean fractional anisotropy.

The FDA cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval.

The randomized, double-blind, placebo-controlled trial will enroll approximately 2900 people with migraine and will evaluate the efficacy and safety of 100- and 200-mg zavegepant.

A recently completed phase 1 program found that ITI-1284 ODT-SL was rapidly absorbed into the systemic circulation, was metabolically stable, and resulted in high systemic exposure.

Compared to participants who never experienced a head injury, a history of a single prior head injury was associated with a 1.25 times increased risk of dementia.

The SINBAR EMG, percentage of RWA from mentalis tonic and any activity, and percentage of RWA from FDS phasic activity all correlated with both disease duration and levodopa-equivalent dose.

Solomon L Moshe, MD, and Elissa Yozawitz, MD, from Montefiore Medical Center, discussed ways of reducing misdiagnosis of neonatal seizures and the future work needed to be done in this space.

Just over half (53%) of patients treated with the amantadine extended-release agent had greater than 50% reduction in time spent ON with dyskinesia and just over a quarter (27%) of patients had greater than 75% reduction.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.

Dosing will be paused in the open-label extension study (GEN-EXTEND) of tominersen while data are carefully analyzed to inform next steps on this study.

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning, while keeping a favorable safety profile in adult and elderly patients.

In the phase 3 ADVANCE trial, all active treatment arms of atogepant met their primary end point, and the 30-mg and 60-mg doses met all 6 secondary end points with statistical significance.

Patients treated with NurOwn showed a mean improvement from baseline of 10% in timed 25-foot walk and a 4.9% improvement from baseline on the 9-hole peg test dominant hand.

The PoNS device becomes the first and only medical device cleared in the US for short-term treatment of gait in patients with multiple sclerosis.

The triage software yielded a sensitivity and specificity of 59.7% and 91.5%, respectively, for all scans in a study including more than 1000.

Behavioral abnormalities, reported from 14 studies, highlighted autistic-like traits and attention and hyperactivity disorders, slightly improving with age in patients with Dravet syndrome.

An overview of the NeurologyLive tweet chat honoring Multiple Sclerosis Awareness Month, featuring highlighted contributions from the medical community.

P values showed evidence of statistical significance at the conventional P <.05 threshold for all assessed non-inferiority margins.

There was very good to excellent level of agreement between the instrumented insoles and the gold-standard reference system.